Remicade biosimilar options for affordable treatment
The Checkup by Singlecare
MAY 16, 2024
From a breakthrough drug to standard-of-care treatment, Remicade (infliximab) has a storied history of treating autoimmune disease —when the immune system mistakenly identifies healthy tissues as foreign and initiates an attack. Inflectra Approved by the FDA in 2016, Inflectra (infliximab-dyyb) was the first biosimilar to Remicade.
Let's personalize your content